毒扁豆碱治疗抗胆碱能谵妄优于非解毒剂治疗:来自区域中毒中心的前瞻性研究
该前瞻性观察分析纳入单个区域中毒中心会诊处理的抗胆碱能谵妄患者,最常见暴露类别为抗组胺药(68%)、镇痛药(19%)和抗精神病药(19%)。中毒信息专家按临床指南推荐毒扁豆碱,但治疗团队仅在37%的推荐病例中实际给药。初始识别后2小时评估,毒扁豆碱组谵妄控制率79%,非解毒剂组36%,谵妄控制的比值比为6.6。不良事件(心动过缓、呕吐、癫痫)罕见且组间无显著差异,毒扁豆碱与插管或约束使用率变化无关。
要点
- 在区域中毒中心会诊的抗胆碱能谵妄患者中,接受毒扁豆碱者2小时谵妄控制率为79%,未接受者为36%(OR 6.6)。
- 毒扁豆碱组与非解毒剂组的不良事件(心动过缓、呕吐、癫痫)均罕见且无显著差异。
- 毒扁豆碱的使用与插管或物理约束的发生率变化无关。
- 中毒信息专家在81%(125例)的病例中推荐毒扁豆碱,但治疗团队仅在37%(57例)的推荐病例中实际给药。
- 最常见暴露类别为抗组胺药(68%)、镇痛药(19%)和抗精神病药(19%)。
适用人群与场景
- 诊断为抗胆碱能谵妄并在单个区域中毒中心会诊下治疗的患者,共纳入154例分析。
- 最常见暴露类别为抗组胺药(68%)、镇痛药(19%)和抗精神病药(19%)。
处置流程与药物剂量
- 中毒信息专家使用临床指南推荐毒扁豆碱的使用。
- 在81%(125例)的病例中中毒信息专家推荐毒扁豆碱,治疗团队在37%(57例)的推荐病例中给予毒扁豆碱。
研究设计与关键结果
- 前瞻性观察分析,单个区域中毒中心,纳入154例抗胆碱能谵妄患者进行分析。
- 初始识别后2小时,毒扁豆碱组谵妄控制率为79%,非解毒剂治疗组为36%。
- 接受毒扁豆碱的患者谵妄控制的比值比(OR)为6.6,高于非解毒剂治疗组。
- 不良事件(心动过缓、呕吐、癫痫)罕见且组间无显著差异。
- 毒扁豆碱与插管或约束使用率变化无关。
证据类型、等级与局限
- 证据类型:前瞻性观察性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该研究进一步提供了毒扁豆碱治疗抗胆碱能谵妄的安全性和有效性证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Poison centers (PCs) frequently manage patients with antimuscarinic delirium. However, controversy surrounds the antidotal use of physostigmine for its treatment. The aim of this study was to prospectively investigate physostigmine versus non-antidote therapy for the management of antimuscarinic delirium in a single regional PC.
METHODS: This was a prospective observational analysis of patients diagnosed with antimuscarinic delirium and treated in consultation with a regional PC. Certified Specialists in Poison Information (CSPIs) use a clinical guideline to recommend the use of physostigmine. Using a previously derived altered mental status score, we quantified the rate of delirium improvement with physostigmine compared to non-antidote therapy two hours after initial patient identification. We also recorded adverse events (defined a priori as bradycardia, vomiting, seizures) and resource utilization (intubation and physical restraint).
RESULTS: We identified 245 patients and included 154 in the analysis. The most common exposure classes were antihistamines (68%), analgesics (19%), and antipsychotics (19%). CSPIs recommended physostigmine in 81% (125) of cases and the treatment team administered it in 37% (57) of these. We observed delirium control in 79% of patients who received physostigmine versus 36% of those who did not. The odds of delirium control were six times greater for patients receiving physostigmine than for patients treated with non-antidote therapy (OR 6.6). Adverse events were rare and did not differ significantly between the groups. Physostigmine was not associated with changes in the incidence of intubation or restraint.
CONCLUSIONS: This study provides further evidence of both the safety and efficacy of physostigmine in the treatment of antimuscarinic delirium.
参考来源
- Boley SP, Olives TD, Bangh SA, et al. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. Clin Toxicol (Phila). 2018. PMID: 29956570. doi:10.1080/15563650.2018.1485154
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。